Table 1.
Characteristics of patients receiving intravitreal aflibercept and ranibizumab injections for neovascular age-related macular degeneration, US.
| Ranibizumab injections (n = 253,647) |
Aflibercept injections (n = 179,147) |
|
|---|---|---|
| Patients receiving injections, n | 54,551 | 39,389 |
| Median age at injection, yearsa | 83.0 | 82.0 |
| Injections by age group, n (%)a | ||
| <65 years | 9138 (3.6) | 5602 (3.1) |
| 65–69 years | 12,550 (4.9) | 11,022 (6.2) |
| 70–74 years | 25,468 (10.0) | 21,569 (12.0) |
| 75–79 years | 43,081 (17.0) | 32,778 (18.3) |
| 80–84 years | 62,176 (24.5) | 45,244 (25.3) |
| ≥85 years | 101,234 (39.9) | 62,932 (35.1) |
| Injections given to women, n (%)a | 163,626 (64.5) | 111,202 (62.1) |
| Injections by prescribing physician, n (%)a | ||
| Ophthalmologist/retinal specialist/eye care doctor | 250,643 (98.8) | 176,186 (98.3) |
| Other/unknown | 3004 (1.2) | 2961 (1.7) |
| Injections by payer type, n (%)a | ||
| Commercial | 40,360 (15.9) | 26,967 (15.1) |
| Medicare | 211,399 (83.3) | 151,799 (84.7) |
| Medicaid | 1888 (0.7) | 381 (0.2) |
| Injections by injection eye, n (%) | ||
| Left | 125,791 (49.6) | 89,344 (49.9) |
| Right | 127,856 (50.4) | 89,803 (50.1) |
| Injections by geographic region, n (%)a | ||
| Northeast | 55,335 (21.8) | 46,078 (25.7) |
| Midwest | 40,871 (16.1) | 38,225 (21.3) |
| South | 112,702 (44.4) | 67,462 (37.7) |
| West | 44,739 (17.6) | 27,381 (15.3) |
| Unknown | − | 1 (0.0) |
| Injections by place of administration, n (%)a | ||
| Physician office | 244,157 (96.3) | 173,175 (96.7) |
| Ambulatory surgical center | 176 (0.1) | 146 (0.1) |
| Outpatient hospital | 1 (0.0) | – |
| Emergency department | 918 (0.4) | 321 (0.2) |
| Other | 16 (0.0) | 10 (0.0) |
| Unknown/missing | 8379 (3.3) | 5495 (3.1) |
a p < 0.0001 for ranibizumab vs. aflibercept across category.
SD, standard deviation.